Equity grants expand ADMA (NASDAQ: ADMA) director Guiheen’s holdings

Rhea-AI Filing Summary

ADMA Biologics director Lawrence P. Guiheen reported new equity awards and updated his holdings. On February 9, 2026, he received 10,690 restricted stock units at $0 and a stock option for 17,730 shares at an exercise price of $16.37.

The RSUs vest in two equal installments on the six- and 12‑month anniversaries of the grant date, becoming fully vested on February 9, 2027, subject to continued service. The options vest in twelve equal monthly installments over one year. After these grants, he directly beneficially owns 105,520 shares of common stock and indirectly holds 50,990 shares through the Lawrence P Guiheen Irrevocable Trust 1.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guiheen Lawrence P.

(Last) (First) (Middle)

C/O ADMA BIOLOGICS, INC.

465 STATE ROUTE 17

(Street)

RAMSEY NJ 07446

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/09/2026		A		10,690(1)	A	$0	105,520(2)	D
Common Stock								50,990	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16.37	02/09/2026		A		17,730		(4)	02/09/2036	Common Stock	17,730	$0	17,730	D

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service as of the applicable vesting date.

2. Includes, as of the transaction date, (i) 10,690 RSUs granted on February 9, 2026, which will fully vest on February 9, 2027, subject to the Reporting Person's continued service as of such vesting date; (ii) 5,445 RSUs out of 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the Reporting Person's continued service as of such vesting date; and (iii) 89,385 shares of common stock owned by the Reporting Person.

3. Includes 50,990 shares of common stock held in the Lawrence P Guiheen Irrevocable Trust 1.

4. These options vest in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.

	/s/ Lawrence P. Guiheen, by Michael A. Goldstein as Attorney-in-fact	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ADMA (ADMA) director Lawrence P. Guiheen report?

Lawrence P. Guiheen reported equity awards from ADMA Biologics, including restricted stock units and stock options. The filing details new grants, vesting terms, and his updated direct and indirect ownership in ADMA common stock, clarifying his overall equity stake in the company.

How many RSUs did ADMA (ADMA) grant to director Lawrence P. Guiheen?

ADMA Biologics granted 10,690 restricted stock units to director Lawrence P. Guiheen. These RSUs vest in two equal installments on the six- and 12-month anniversaries of the February 9, 2026 grant date, becoming fully vested on February 9, 2027, subject to his continued service.

What stock options did ADMA (ADMA) grant to Lawrence P. Guiheen?

Guiheen received a stock option covering 17,730 ADMA Biologics common shares at an exercise price of $16.37. The option vests in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the February 9, 2026 grant date, contingent on continued service.

What is Lawrence P. Guiheen’s direct ADMA (ADMA) share ownership after this Form 4?

Following the reported transactions, Guiheen directly beneficially owns 105,520 shares of ADMA Biologics common stock. This figure includes previously held shares and the newly granted restricted stock units, as described in the Form 4 and its accompanying explanatory footnotes.

Does Lawrence P. Guiheen have indirect ownership of ADMA (ADMA) shares?

Yes. The filing states that 50,990 ADMA Biologics common shares are held indirectly in the Lawrence P Guiheen Irrevocable Trust 1. This position is reported as indirect beneficial ownership, separate from his directly held ADMA common stock and equity awards.

What are the vesting conditions on ADMA (ADMA) RSUs granted February 9, 2026?

The 10,690 RSUs granted February 9, 2026 vest in two equal tranches on the six- and 12-month anniversaries of the grant. They become fully vested on February 9, 2027, provided Guiheen continues to serve through each applicable vesting date.

How do previously granted ADMA (ADMA) RSUs factor into Guiheen’s holdings?

The filing notes 5,445 RSUs remaining from a 10,889-unit grant dated February 19, 2025. These RSUs are scheduled to vest fully on February 19, 2026, assuming continued service, and are included within Guiheen’s reported direct beneficial ownership figure.